No abstract

A double-blind crossover study of the effects of baclofen was conducted on 10 patients with typical trigeminal neuralgia. Baclofen significantly decreased the number of painful paroxysms in 7 of the 10 patients. An open trial in another 50 patients with trigeminal neuralgia refractory to or unable to tolerate carbamazepine showed that 37 (74%) were relieved of their attacks by baclofen, either alone (12 patients) or in combination with previously ineffective doses of carbamazepine or phenytoin (25). On long-term follow-up of one to five years (mean, 3.0 years), 18 of the 60 patients (30%) continued pain free while receiving baclofen; 10 (17%) went into remission after 3 to 6 months; 13 (22%) became refractory to baclofen after 1 to 18 months; and 2 (3%) elected operation despite a good response to baclofen. The results indicate that baclofen is a useful drug in the treatment of trigeminal neuralgia.

No abstract

No abstract

Although trigeminal neuralgia and atypical facial pain can usually be distinguished on the basis of several well-established criteria, differential diagnosis is difficult in a small number of patients. The purpose of this study was to determine whether the McGill Pain Questionnaire (MPQ) is capable of discriminating between the two syndromes and might therefore serve as a diagnostic aid. The MPQ was administered to 74 patients in Pittsburgh and the data were analyzed statistically in Montreal. In an analysis of the data of 53 patients, 91% of the patients were correctly classified on the basis of 7 descriptors. To determine whether the key descriptors were able to predict the diagnosis of a second group, the discriminant function derived from the first analysis was applied to a new group of 21 patients. A correct prediction was made for 90% of the patients. The results indicate that, in difficult cases, the MPQ may be a useful tool to aid in differential diagnosis.